TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Buys 75,500 Shares of Stock

TScan Therapeutics, Inc. (NASDAQ:TCRX) major shareholder Lynx1 Capital Management Lp acquired 75,500 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average price of $0.90 per share, with a total value of $67,950.00. Following the completion of the acquisition, the insider owned 8,012,916 shares of the company’s stock, valued at $7,211,624.40. This represents a 0.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Lynx1 Capital Management Lp also recently made the following trade(s):

• On Tuesday, December 23rd, Lynx1 Capital Management Lp bought 6,232 shares of TScan Therapeutics stock. The stock was acquired at an average price of $0.90 per share, with a total value of $5,608.80.
• On Friday, December 19th, Lynx1 Capital Management Lp acquired 80,069 shares of TScan Therapeutics stock. The stock was acquired at an average price of $0.90 per share, with a total value of $72,062.10.

TScan Therapeutics Stock Performance

TCRX opened at $0.91 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.44 and a current ratio of 6.44. The company has a market cap of $51.68 million, a PE ratio of -0.81 and a beta of 1.03. The stock has a 50-day moving average of $1.35 and a 200-day moving average of $1.62. TScan Therapeutics, Inc. has a 52-week low of $0.88 and a 52-week high of $3.43.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The business had revenue of $2.51 million for the quarter, compared to analyst estimates of $1.98 million. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%. As a group, equities research analysts forecast that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC bought a new position in TScan Therapeutics in the first quarter valued at about $49,000. Checkpoint Capital L.P. lifted its position in TScan Therapeutics by 14.9% during the 1st quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock valued at $2,784,000 after purchasing an additional 261,663 shares during the period. BVF Inc. IL boosted its stake in shares of TScan Therapeutics by 63.6% in the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock valued at $6,747,000 after purchasing an additional 1,900,000 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after buying an additional 9,676 shares during the period. Finally, Deutsche Bank AG raised its stake in shares of TScan Therapeutics by 149.4% during the first quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock worth $73,000 after buying an additional 31,481 shares during the last quarter. Institutional investors and hedge funds own 82.83% of the company’s stock.

Wall Street Analysts Forecast Growth

TCRX has been the subject of a number of recent research reports. BTIG Research lowered TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th. HC Wainwright dropped their price objective on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Morgan Stanley downgraded shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a report on Friday, November 14th. Needham & Company LLC lowered their target price on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.60.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.